Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/ct2/show/NCT00373425
Registration number
NCT00373425
Ethics application status
Date submitted
7/09/2006
Date registered
8/09/2006
Date last updated
17/09/2015
Titles & IDs
Public title
A Study of Erlotinib (Tarceva) After Surgery With or Without Adjuvant Chemotherapy in Non-Small Cell Lung Carcinoma (NSCLC) Patients Who Have Epidermal Growth Factor Receptor (EGFR) Positive Tumors
Query!
Scientific title
A Multi-center, Randomized, Double-blind, Placebo-controlled, Phase 3 Study of Single-agent Tarceva® (Erlotinib) Following Complete Tumor Resection With or Without Adjuvant Chemotherapy in Patients With Stage IB-IIIA Non-small Cell Lung Carcinoma Who Have EGFR-positive Tumors
Query!
Secondary ID [1]
0
0
2005-001747-29
Query!
Secondary ID [2]
0
0
OSI-774-302
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
RADIANT
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Non-small Cell Lung Cancer
0
0
Query!
Condition category
Condition code
Cancer
0
0
0
0
Query!
Lung - Mesothelioma
Query!
Cancer
0
0
0
0
Query!
Lung - Non small cell
Query!
Cancer
0
0
0
0
Query!
Lung - Small cell
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - Erlotinib
Treatment: Drugs - Placebo
Experimental: Erlotinib - Participants received 150 mg/day erlotinib orally for 2 years or until relapse, death, participant request or investigator decision to discontinue study drug, or intolerable toxicity.
Placebo Comparator: Placebo - Participants received matching placebo tablets orally for 2 years or until relapse, death, participant request or investigator decision to discontinue study drug, or intolerable toxicity.
Treatment: Drugs: Erlotinib
150 mg tablet
Treatment: Drugs: Placebo
Placebo tablet
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Disease Free Survival (DFS)
Query!
Assessment method [1]
0
0
DFS is the time from the date of randomization until the first day non-small cell lung cancer (NSCLC) relapse is documented by radiological exam and/or biopsy, or until death in the absence of relapse. After randomization, NSCLC relapse was based on radiological evidence or biopsy, as determined by the investigator. Participants without a DFS event were censored on the last adequate radiological assessment date.
Query!
Timepoint [1]
0
0
Every 3 months during active phase and every 6 months during long term follow-up up to 5 years and yearly thereafter until the data cut-off date of 08 April 2013 (maximum time on follow-up was 64 months).
Query!
Primary outcome [2]
0
0
Disease Free Survival (DFS)
Query!
Assessment method [2]
0
0
DFS is the time from the date of randomization until the first day that non-small cell lung cancer (NSCLC) relapse is documented by radiological exam and/or biopsy, or until death in the absence of relapse. After randomization, NSCLC relapse was based on radiological evidence or biopsy, as determined by the investigator. Participants without a DFS event were censored on the last adequate radiological assessment date.
Query!
Timepoint [2]
0
0
Every 3 months during active phase and every 6 months during long term follow-up up to 5 years and yearly thereafter until the data cutoff date of 11 June 2014 (maximum time on follow-up was 78 months).
Query!
Secondary outcome [1]
0
0
Overall Survival (OS)
Query!
Assessment method [1]
0
0
Overall survival was defined as the time from the date of randomization until the documented date of death. Participants who were still alive were censored on the last day they were known to be alive.
Query!
Timepoint [1]
0
0
Every 3 months during active phase and every 6 months during long term follow-up up to 5 years and yearly thereafter until the data cut-off date of 08 April 2013 (maximum time on follow-up was 64 months).
Query!
Secondary outcome [2]
0
0
Overall Survival (OS)
Query!
Assessment method [2]
0
0
Overall survival was defined as the time from the date of randomization until the documented date of death. Participants who were still alive were censored on the last day they were known to be alive.
Query!
Timepoint [2]
0
0
Every 3 months during active phase and every 6 months during long term follow-up up to 5 years and yearly thereafter until the data cut-off date of 11 June 2014 (maximum time on follow-up was 78 months).
Query!
Secondary outcome [3]
0
0
Disease-free Survival in Participants With EGFR Mutation - Positive Tumors
Query!
Assessment method [3]
0
0
Disease-free survival (DFS) is the time from the date of randomization until the first day NSCLC relapse is documented by radiological exam and/or biopsy, or until death in the absence of relapse. After randomization, NSCLC relapse was based on radiological evidence or biopsy, as determined by the investigator. Participants without a DFS event were censored on the last adequate radiological assessment date. Activating EGFR mutation-positive is defined as exon 19 deletion or exon 21 L858R (or both) detected.
Query!
Timepoint [3]
0
0
Every 3 months during active phase and every 6 months during long term follow-up up to 5 years and yearly thereafter until the data cut-off date of 08 April 2013 (maximum time on follow-up was 64 months).
Query!
Secondary outcome [4]
0
0
Disease-free Survival in Participants With EGFR Mutation - Positive Tumors
Query!
Assessment method [4]
0
0
Disease-free survival (DFS) is the time from the date of randomization until the first day NSCLC relapse is documented by radiological exam and/or biopsy, or until death in the absence of relapse. After randomization, NSCLC relapse was based on radiological evidence or biopsy, as determined by the investigator. Participants without a DFS event were censored on the last adequate radiological assessment date. Activating EGFR mutation-positive is defined as exon 19 deletion or exon 21 L858R (or both) detected.
Query!
Timepoint [4]
0
0
Every 3 months during active phase and every 6 months during long term follow-up up to 5 years and yearly thereafter until the data cut-off date of 11 June 2014 (maximum time on follow-up was 78 months).
Query!
Secondary outcome [5]
0
0
Overall Survival in Participants With EGFR Mutation - Positive Tumors
Query!
Assessment method [5]
0
0
Overall survival is defined as the time from the date of randomization until the documented date of death. Participants who were still alive were censored on the last day they were known to be alive.
Activating EGFR mutation-positive is defined as exon 19 deletion or exon 21 L858R (or both) detected.
Query!
Timepoint [5]
0
0
Every 3 months during active phase and every 6 months during long term follow-up up to 5 years and yearly thereafter until the data cut-off date of 08 April 2013 (maximum time on follow-up was 64 months)
Query!
Secondary outcome [6]
0
0
Overall Survival in Participants With EGFR Mutation - Positive Tumors
Query!
Assessment method [6]
0
0
Overall survival is defined as the time from the date of randomization until the documented date of death. Participants who were still alive were censored on the last day they were known to be alive.
Activating EGFR mutation-positive is defined as exon 19 deletion or exon 21 L858R (or both) detected.
Query!
Timepoint [6]
0
0
Every 3 months during active phase and every 6 months during long term follow-up up to 5 years and yearly thereafter until the data cut-off date of 11 June 2014 (maximum time on follow-up was 78 months)
Query!
Secondary outcome [7]
0
0
Number of Participants With Adverse Events (AEs)
Query!
Assessment method [7]
0
0
An AE was defined as any untoward medical occurrence in a study participant and did not necessarily have a causal relationship with study treatment.
An AE was considered serious if it resulted in death, a life-threatening situation, inpatient hospitalization or prolongation of existing hospitalization, persistent or significant disability/incapacity, congenital anomaly/birth defect in the offspring of a participant, other important medical events, or is on the Astellas Always Serious List.
A drug-related AE was any AE with at least a possible relationship to study treatment as assessed by the investigator. Severity was graded by the investigator according to the National Cancer Institute Common Terminology Criteria for Adverse Events, v3.0, where Grade 1=Mild AE; Grade=2 Moderate AE; Grade 3=Severe AE; Grade 4=Life-threatening or disabling; Grade 5=Death related to AE. AEs leading to death include deaths that occurred more than 30 days after the last dose of study drug.
Query!
Timepoint [7]
0
0
From the date of first dose of study drug until 30 days after the last dose. The median time on treatment was 11.9 months for erlotinib and 21.9 months for placebo. Data are based off the 11 June 2014 data cut-off date.
Query!
Eligibility
Key inclusion criteria
- Primary tissue from patient's surgery must be epidermal growth factor receptor
(EGFR)-positive by certain tests
- Patients may have up to 4 cycles of chemotherapy after surgery
- Complete removal of the tumor by surgery
- Able to start drug under the following timelines:
- 6 months from the day of surgery for patients who get chemotherapy
- 3 months from the day of surgery for those who do not get chemotherapy
- Confirmed diagnosis of Stage IB-IIIA NSCLC
- Patients must be accessible for follow-up visits
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
- History of prior radiotherapy for NSCLC either before or after surgery
- History of heart disease or uncontrolled heart arrhythmias within the previous year
- History of poorly controlled gastrointestinal (GI) disorders that could affect the
absorption of study drug
- History of other cancer except certain skin or cervical cancers, patients who have had
other cancer are eligible if they have remained disease free for at least 5 years
- Patients who have received chemotherapy for NSCLC before surgery
- Tumors with mixed histology of NSCLC and Small Cell Lung Cancer (SCLC). Patients with
carcinoid tumors are not eligible.
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Blinded (masking used)
Query!
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 3
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Completed
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
1/09/2006
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
1/06/2014
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
1252
Query!
Recruitment in Australia
Recruitment state(s)
NSW,VIC
Query!
Recruitment hospital [1]
0
0
Campbelltown Hospital - Campbelltown
Query!
Recruitment hospital [2]
0
0
Liverpool Hospital - Liverpool
Query!
Recruitment hospital [3]
0
0
Royal North Shore Hospital - St Leonards
Query!
Recruitment hospital [4]
0
0
Monash Medical Centre - East Bentleigh
Query!
Recruitment hospital [5]
0
0
St Vincent's Hospital Melbourne - Fitzroy
Query!
Recruitment hospital [6]
0
0
Austin Hospital - Heidelberg
Query!
Recruitment hospital [7]
0
0
Respiratory Clinical Trials Pty., Ltd - Adelaide
Query!
Recruitment hospital [8]
0
0
Ashford Cancer Centre - Ashford
Query!
Recruitment postcode(s) [1]
0
0
2560 - Campbelltown
Query!
Recruitment postcode(s) [2]
0
0
2170 - Liverpool
Query!
Recruitment postcode(s) [3]
0
0
2065 - St Leonards
Query!
Recruitment postcode(s) [4]
0
0
3165 - East Bentleigh
Query!
Recruitment postcode(s) [5]
0
0
3065 - Fitzroy
Query!
Recruitment postcode(s) [6]
0
0
3084 - Heidelberg
Query!
Recruitment postcode(s) [7]
0
0
5067 - Adelaide
Query!
Recruitment postcode(s) [8]
0
0
SA 5037 - Ashford
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
Alabama
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
Arizona
Query!
Country [3]
0
0
United States of America
Query!
State/province [3]
0
0
Arkansas
Query!
Country [4]
0
0
United States of America
Query!
State/province [4]
0
0
California
Query!
Country [5]
0
0
United States of America
Query!
State/province [5]
0
0
Colorado
Query!
Country [6]
0
0
United States of America
Query!
State/province [6]
0
0
Connecticut
Query!
Country [7]
0
0
United States of America
Query!
State/province [7]
0
0
Florida
Query!
Country [8]
0
0
United States of America
Query!
State/province [8]
0
0
Georgia
Query!
Country [9]
0
0
United States of America
Query!
State/province [9]
0
0
Idaho
Query!
Country [10]
0
0
United States of America
Query!
State/province [10]
0
0
Illinois
Query!
Country [11]
0
0
United States of America
Query!
State/province [11]
0
0
Indiana
Query!
Country [12]
0
0
United States of America
Query!
State/province [12]
0
0
Kansas
Query!
Country [13]
0
0
United States of America
Query!
State/province [13]
0
0
Kentucky
Query!
Country [14]
0
0
United States of America
Query!
State/province [14]
0
0
Louisiana
Query!
Country [15]
0
0
United States of America
Query!
State/province [15]
0
0
Maine
Query!
Country [16]
0
0
United States of America
Query!
State/province [16]
0
0
Maryland
Query!
Country [17]
0
0
United States of America
Query!
State/province [17]
0
0
Massachusetts
Query!
Country [18]
0
0
United States of America
Query!
State/province [18]
0
0
Michigan
Query!
Country [19]
0
0
United States of America
Query!
State/province [19]
0
0
Minnesota
Query!
Country [20]
0
0
United States of America
Query!
State/province [20]
0
0
Missouri
Query!
Country [21]
0
0
United States of America
Query!
State/province [21]
0
0
Nebraska
Query!
Country [22]
0
0
United States of America
Query!
State/province [22]
0
0
Nevada
Query!
Country [23]
0
0
United States of America
Query!
State/province [23]
0
0
New Hampshire
Query!
Country [24]
0
0
United States of America
Query!
State/province [24]
0
0
New Jersey
Query!
Country [25]
0
0
United States of America
Query!
State/province [25]
0
0
New Mexico
Query!
Country [26]
0
0
United States of America
Query!
State/province [26]
0
0
New York
Query!
Country [27]
0
0
United States of America
Query!
State/province [27]
0
0
North Carolina
Query!
Country [28]
0
0
United States of America
Query!
State/province [28]
0
0
Ohio
Query!
Country [29]
0
0
United States of America
Query!
State/province [29]
0
0
Oregon
Query!
Country [30]
0
0
United States of America
Query!
State/province [30]
0
0
Pennsylvania
Query!
Country [31]
0
0
United States of America
Query!
State/province [31]
0
0
South Carolina
Query!
Country [32]
0
0
United States of America
Query!
State/province [32]
0
0
Tennessee
Query!
Country [33]
0
0
United States of America
Query!
State/province [33]
0
0
Texas
Query!
Country [34]
0
0
United States of America
Query!
State/province [34]
0
0
Virginia
Query!
Country [35]
0
0
United States of America
Query!
State/province [35]
0
0
Washington
Query!
Country [36]
0
0
Argentina
Query!
State/province [36]
0
0
Buenos Aires
Query!
Country [37]
0
0
Argentina
Query!
State/province [37]
0
0
Mendoza
Query!
Country [38]
0
0
Argentina
Query!
State/province [38]
0
0
Rosario, Santa Fe
Query!
Country [39]
0
0
Argentina
Query!
State/province [39]
0
0
Santa Fé
Query!
Country [40]
0
0
Austria
Query!
State/province [40]
0
0
Innsbruck
Query!
Country [41]
0
0
Austria
Query!
State/province [41]
0
0
Linz
Query!
Country [42]
0
0
Austria
Query!
State/province [42]
0
0
Salzburg
Query!
Country [43]
0
0
Austria
Query!
State/province [43]
0
0
Wien
Query!
Country [44]
0
0
Belgium
Query!
State/province [44]
0
0
Brussels
Query!
Country [45]
0
0
Belgium
Query!
State/province [45]
0
0
Charleroi
Query!
Country [46]
0
0
Belgium
Query!
State/province [46]
0
0
La Louvière
Query!
Country [47]
0
0
Canada
Query!
State/province [47]
0
0
Alberta
Query!
Country [48]
0
0
Canada
Query!
State/province [48]
0
0
Ontario
Query!
Country [49]
0
0
Canada
Query!
State/province [49]
0
0
Quebec
Query!
Country [50]
0
0
Canada
Query!
State/province [50]
0
0
Toronto
Query!
Country [51]
0
0
Czech Republic
Query!
State/province [51]
0
0
Ceske Budejovice
Query!
Country [52]
0
0
Czech Republic
Query!
State/province [52]
0
0
Ostrava-Poruba
Query!
Country [53]
0
0
Czech Republic
Query!
State/province [53]
0
0
Praha
Query!
Country [54]
0
0
France
Query!
State/province [54]
0
0
Cedex 9
Query!
Country [55]
0
0
France
Query!
State/province [55]
0
0
Bayonne
Query!
Country [56]
0
0
France
Query!
State/province [56]
0
0
Brest cedex
Query!
Country [57]
0
0
France
Query!
State/province [57]
0
0
Caen Cedex
Query!
Country [58]
0
0
France
Query!
State/province [58]
0
0
Clermont-Ferrand cedex 1
Query!
Country [59]
0
0
France
Query!
State/province [59]
0
0
Lyon cedex 04
Query!
Country [60]
0
0
France
Query!
State/province [60]
0
0
Marseille cedex 9
Query!
Country [61]
0
0
France
Query!
State/province [61]
0
0
PARIS cedex 14
Query!
Country [62]
0
0
France
Query!
State/province [62]
0
0
Paris
Query!
Country [63]
0
0
France
Query!
State/province [63]
0
0
Perpignan
Query!
Country [64]
0
0
France
Query!
State/province [64]
0
0
Rennes cedex 9
Query!
Country [65]
0
0
France
Query!
State/province [65]
0
0
Saint Priest en Jarez
Query!
Country [66]
0
0
France
Query!
State/province [66]
0
0
Vandoeuvre-lès-Nancy Cedex
Query!
Country [67]
0
0
Germany
Query!
State/province [67]
0
0
Bad Berka
Query!
Country [68]
0
0
Germany
Query!
State/province [68]
0
0
Berlin
Query!
Country [69]
0
0
Germany
Query!
State/province [69]
0
0
Bochum
Query!
Country [70]
0
0
Germany
Query!
State/province [70]
0
0
Coswig
Query!
Country [71]
0
0
Germany
Query!
State/province [71]
0
0
Essen
Query!
Country [72]
0
0
Germany
Query!
State/province [72]
0
0
Frankfurt/Main
Query!
Country [73]
0
0
Germany
Query!
State/province [73]
0
0
Freiburg
Query!
Country [74]
0
0
Germany
Query!
State/province [74]
0
0
Großhansdorf
Query!
Country [75]
0
0
Germany
Query!
State/province [75]
0
0
Göttingen
Query!
Country [76]
0
0
Germany
Query!
State/province [76]
0
0
Halle (Saale)
Query!
Country [77]
0
0
Germany
Query!
State/province [77]
0
0
Hamburg
Query!
Country [78]
0
0
Germany
Query!
State/province [78]
0
0
Heidelberg
Query!
Country [79]
0
0
Germany
Query!
State/province [79]
0
0
Hemer
Query!
Country [80]
0
0
Germany
Query!
State/province [80]
0
0
Karlsruhe
Query!
Country [81]
0
0
Germany
Query!
State/province [81]
0
0
Lübeck
Query!
Country [82]
0
0
Germany
Query!
State/province [82]
0
0
Mainz
Query!
Country [83]
0
0
Germany
Query!
State/province [83]
0
0
Muenchen-Gauting
Query!
Country [84]
0
0
Germany
Query!
State/province [84]
0
0
Oldenburg
Query!
Country [85]
0
0
Germany
Query!
State/province [85]
0
0
Villingen-Schwenningen
Query!
Country [86]
0
0
Greece
Query!
State/province [86]
0
0
Athens
Query!
Country [87]
0
0
Greece
Query!
State/province [87]
0
0
Thessaloniki
Query!
Country [88]
0
0
Hungary
Query!
State/province [88]
0
0
Budapest
Query!
Country [89]
0
0
Hungary
Query!
State/province [89]
0
0
Deszk
Query!
Country [90]
0
0
Hungary
Query!
State/province [90]
0
0
Pécs
Query!
Country [91]
0
0
Hungary
Query!
State/province [91]
0
0
Szekesfehervar
Query!
Country [92]
0
0
Hungary
Query!
State/province [92]
0
0
Szombathely
Query!
Country [93]
0
0
Italy
Query!
State/province [93]
0
0
Ancona
Query!
Country [94]
0
0
Italy
Query!
State/province [94]
0
0
Bologna
Query!
Country [95]
0
0
Italy
Query!
State/province [95]
0
0
Catania
Query!
Country [96]
0
0
Italy
Query!
State/province [96]
0
0
Genova
Query!
Country [97]
0
0
Italy
Query!
State/province [97]
0
0
Parma
Query!
Country [98]
0
0
Italy
Query!
State/province [98]
0
0
Perugia
Query!
Country [99]
0
0
Italy
Query!
State/province [99]
0
0
Roma
Query!
Country [100]
0
0
Korea, Republic of
Query!
State/province [100]
0
0
Gyeonggi-Do
Query!
Country [101]
0
0
Korea, Republic of
Query!
State/province [101]
0
0
Incheon
Query!
Country [102]
0
0
Korea, Republic of
Query!
State/province [102]
0
0
Seoul
Query!
Country [103]
0
0
Poland
Query!
State/province [103]
0
0
Lublin
Query!
Country [104]
0
0
Poland
Query!
State/province [104]
0
0
Otwock
Query!
Country [105]
0
0
Poland
Query!
State/province [105]
0
0
Poznan
Query!
Country [106]
0
0
Poland
Query!
State/province [106]
0
0
Szczecin
Query!
Country [107]
0
0
Poland
Query!
State/province [107]
0
0
Warsaw
Query!
Country [108]
0
0
Poland
Query!
State/province [108]
0
0
Wroclaw
Query!
Country [109]
0
0
Romania
Query!
State/province [109]
0
0
Bihor
Query!
Country [110]
0
0
Romania
Query!
State/province [110]
0
0
Dolj
Query!
Country [111]
0
0
Romania
Query!
State/province [111]
0
0
Bucuresti
Query!
Country [112]
0
0
Romania
Query!
State/province [112]
0
0
Cluj-Napoca
Query!
Country [113]
0
0
Romania
Query!
State/province [113]
0
0
Iasi
Query!
Country [114]
0
0
Romania
Query!
State/province [114]
0
0
Sibiu
Query!
Country [115]
0
0
Russian Federation
Query!
State/province [115]
0
0
Arkhangelsk
Query!
Country [116]
0
0
Russian Federation
Query!
State/province [116]
0
0
Kemerovo
Query!
Country [117]
0
0
Russian Federation
Query!
State/province [117]
0
0
Krasnodar
Query!
Country [118]
0
0
Russian Federation
Query!
State/province [118]
0
0
Moscow
Query!
Country [119]
0
0
Russian Federation
Query!
State/province [119]
0
0
Saint-Petersburg
Query!
Country [120]
0
0
Russian Federation
Query!
State/province [120]
0
0
Tomsk
Query!
Country [121]
0
0
Russian Federation
Query!
State/province [121]
0
0
Yaroslavl
Query!
Country [122]
0
0
Spain
Query!
State/province [122]
0
0
Barcelona
Query!
Country [123]
0
0
Spain
Query!
State/province [123]
0
0
Madrid
Query!
Country [124]
0
0
Spain
Query!
State/province [124]
0
0
Málaga
Query!
Country [125]
0
0
Spain
Query!
State/province [125]
0
0
Pamplona
Query!
Country [126]
0
0
Spain
Query!
State/province [126]
0
0
Santander
Query!
Country [127]
0
0
Spain
Query!
State/province [127]
0
0
Sevilla
Query!
Country [128]
0
0
Spain
Query!
State/province [128]
0
0
Toledo
Query!
Country [129]
0
0
Spain
Query!
State/province [129]
0
0
Valencia
Query!
Country [130]
0
0
Taiwan
Query!
State/province [130]
0
0
Changhua
Query!
Country [131]
0
0
Taiwan
Query!
State/province [131]
0
0
Kaohsiung
Query!
Country [132]
0
0
Taiwan
Query!
State/province [132]
0
0
Taichung
Query!
Country [133]
0
0
Taiwan
Query!
State/province [133]
0
0
Taipei
Query!
Country [134]
0
0
Taiwan
Query!
State/province [134]
0
0
Taoyuan
Query!
Country [135]
0
0
United Kingdom
Query!
State/province [135]
0
0
Birmingham
Query!
Country [136]
0
0
United Kingdom
Query!
State/province [136]
0
0
Bristol
Query!
Country [137]
0
0
United Kingdom
Query!
State/province [137]
0
0
Dundee
Query!
Country [138]
0
0
United Kingdom
Query!
State/province [138]
0
0
Glasgow
Query!
Country [139]
0
0
United Kingdom
Query!
State/province [139]
0
0
Guildford
Query!
Country [140]
0
0
United Kingdom
Query!
State/province [140]
0
0
Lecester
Query!
Country [141]
0
0
United Kingdom
Query!
State/province [141]
0
0
Leeds
Query!
Country [142]
0
0
United Kingdom
Query!
State/province [142]
0
0
London
Query!
Country [143]
0
0
United Kingdom
Query!
State/province [143]
0
0
Sutton
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Query!
Name
OSI Pharmaceuticals
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
This is a study to evaluate the effectiveness of erlotinib compared with a placebo sugar pill
following complete surgical removal of the tumor with or without chemotherapy after surgery
in Stage IB-IIIA NSCLC patients.
Query!
Trial website
https://clinicaltrials.gov/ct2/show/NCT00373425
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Medical Monitor
Query!
Address
0
0
Astellas Pharma Global Development
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
Summary Results
For IPD and results data, please see
https://clinicaltrials.gov/ct2/show/NCT00373425
Download to PDF